Long Acting Release of Byetta

The American Diabetes Association will have the release of the Long Acting Release (LAR) Byetta information at the Annual meeting this June.

It looks good as far as the trials are concerned but the release date so far has not been announced.

The ADA will have a series of announcements as the meeting opens so more information will follow.

BP Meds Causing Diabetes

Decades ago we learned that the drug class of thiazide diuretics given for hypertension reduced the incidence of stroke but increased the incidence of heart attacks.

Now there is an important paper that shows the use of thiazide diuretics and the class of beta blockers will cause diabetes 2. The dose of the Thiazide is over 25 mg to do this and the mechanism of how these two create this problem is through increased insulin resistance. Diabetes Care 29:1065; 1065-1070, 2006

The patients included over 280,000 female nurses and about 52,000 male health professionals.

There are lots of other blood pressure medications that can control blood pressure better while decreasing the incidence of Diabetes. The classes of ACE inhibitors and angiotension II receptor blockers – ARBS – tend to reduce the incidence of diabetes.

The latter two classes of blood pressure medications reduce the incidence of diabetes by decreasing vasoconstriction (small blood vessel disease), fibrosis (scarring in the tissues), inflammation (the prelude to scarring), and decreasing the rate of beta cell death in the islets of Langerhans.

Knowledge of what kind of treatment you need can really be good for you. It’s your time.

Metabolic Syndrome

The Metabolic Syndrome is defined as a cluster of metabolic risk factors that come together in a single individual. This is insulin resistance, high blood presser, and increased cholesterol, decreased HDL and increased triglycerides. It often it has increased “middle fat” in the abdomen.

It is observed in those with type one diabetes and type two. Such an observation gives further strength to the “accelerator theory” of diabetes. Read more.

As we have used Byetta, a medication designated for only those with type 2 diabetes by the FDA, we find that those with type one (C Peptide negative) and evidence of the Metabolic Syndrome respond very well to the use of Byetta.

We are now pulling together all the information on the patients we have treated over the last year and will present this on this E-News. It is really exciting; share it with your friends. It’s your time.

Dr. Joe, the Diabetes Doctor ©